Recently, Nanjing RegeneCore Biotechnology Co., Ltd.'s RC1416 project has consecutively obtained Investigational New Drug (IND) approvals from the National Medical Products Administration's Center for Drug Evaluation (CDE) for indications of atopic dermatitis (AD) and chronic obstructive pulmonary disease (COPD). The expansion of these indications has further diversified the clinical application scenarios of RC1416 injection, providing better treatment options for more patients.

Recently, Nanjing RegeneCore Biotech Co., Ltd. issued a recruitment notice for patients with moderate to severe asthma, drawing widespread attention. It turns out that RC1416 injection—China's first domestically developed autoimmune bispecific nanobody drug independently researched by RegeneCore—is currently undergoing clinical trials at dozens of renowned hospitals nationwide. Demonstrating significant advantages in efficacy, safety, and druggability, this bispecific antibody therapy holds promise as a breakthrough treatment for patients suffering from moderate to severe asthma.